Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial

2008/10/15 by John A Baron, John A. Baron, Robert S. Sandler +13 · 2 citations
Medicine · #Antiplatelet Therapy and Cardiovascular Diseases #Cancer, Stress, Anesthesia, and Immune Response #Inflammatory mediators and NSAID effects

paper · doi:10.1016/s0140-6736(08)61490-7

openalex publication_date 2008/10/15 · crossref created 2008/10/15 · crossref issued 2008/11/01 · crossref published 2008/11/01 · crossref published-print 2008/11/01 · crossref deposited 2025/09/25 · openalex created_date 2025/10/10 · crossref indexed 2026/01/15 · openalex updated_date 2026/07/07

Citations

• Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
• Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
• Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis

Cited by

• Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis
• Nonsteroidal anti-inflammatory drug [wikipedia]